Cytodyn Inc logo

CYDY - Cytodyn Inc Share Price

$3.55 0.1  3.8%

Last Trade - 18/09/20

Sector
Healthcare
Size
Mid Cap
Market Cap £1.56bn
Enterprise Value £1.56bn
Revenue £n/a
Position in Universe 1804th / 6396
Bullish
Bearish
Unlock CYDY Revenue
Momentum
Relative Strength (%)
1m +18.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -64.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st May 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 135
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 May 2020, CytoDyn Inc revenues was not reported. Net loss increased from $56.2M to $124.4M. Higher net loss reflects Change in fair value of derivative liabi decrease from $1.7M (income) to $9.5M (expense), Research and Development increase of 24% to $52.6M (expense), Interest Exp-Net of Capitalized Interes increase from $0K to $7.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CYDY Revenue Unlock CYDY Revenue

Net Income

CYDY Net Income Unlock CYDY Revenue

Normalised EPS

CYDY Normalised EPS Unlock CYDY Revenue

PE Ratio Range

CYDY PE Ratio Range Unlock CYDY Revenue

Dividend Yield Range

CYDY Dividend Yield Range Unlock CYDY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CYDY EPS Forecasts Unlock CYDY Revenue
Profile Summary

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Directors
Last Annual May 31st, 2020
Last Interim May 31st, 2020
Incorporated January 12, 2015
Public Since November 17, 2005
No. of Shareholders: 910
No. of Employees: 19
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 569,068,294
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CYDY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CYDY
Upcoming Events for CYDY
Frequently Asked Questions for Cytodyn Inc
What is the Cytodyn Inc share price?

As of 18/09/20, shares in Cytodyn Inc are trading at $3.55, giving the company a market capitalisation of £1.56bn. This share price information is delayed by 15 minutes.

How has the Cytodyn Inc share price performed this year?

Shares in Cytodyn Inc are currently trading at $3.55 and the price has moved by 0.846k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cytodyn Inc price has moved by 0.778k% over the past year.

What are the analyst and broker recommendations for Cytodyn Inc?

Of the analysts with advisory recommendations for Cytodyn Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cytodyn Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Cytodyn Inc next release its financial results?

Cytodyn Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-05-31
What is the Cytodyn Inc dividend yield?

Cytodyn Inc does not currently pay a dividend.

Does Cytodyn Inc pay a dividend?

Cytodyn Inc does not currently pay a dividend.

When does Cytodyn Inc next pay dividends?

Cytodyn Inc does not currently pay a dividend.

How do I buy Cytodyn Inc shares?

To buy shares in Cytodyn Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cytodyn Inc?

Shares in Cytodyn Inc are currently trading at $3.55, giving the company a market capitalisation of £1.56bn.

Where are Cytodyn Inc shares listed? Where are Cytodyn Inc shares listed?

Here are the trading details for Cytodyn Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: CYDY
What kind of share is Cytodyn Inc?

Based on an overall assessment of its quality, value and momentum, Cytodyn Inc is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cytodyn Inc share price forecast 2020?

Shares in Cytodyn Inc are currently priced at $3.55. At that level they are trading at 12.68% discount to the analyst consensus target price of 0.00.

How can I tell whether the Cytodyn Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytodyn Inc. Over the past six months, the relative strength of its shares against the market has been 0.150k%. At the current price of $3.55, shares in Cytodyn Inc are trading at 30.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cytodyn Inc PE Ratio?

We were not able to find PE ratio data for Cytodyn Inc.

Who are the key directors of Cytodyn Inc?

Cytodyn Inc's management team is headed by:

Nader Pourhassan - PRE
Jordan Naydenov - IND
Michael Mulholland - CFO
Scott Kelly - CHM
Michael Klump - IND
Nitya Ray - CTO
Alan Timmins - IND
Maura Fleming - VPR
Samir Patel - IND
Who are the major shareholders of Cytodyn Inc?

Here are the top five shareholders of Cytodyn Inc based on the size of their shareholding:

Pestell (Richard G) Individual Investor
Percentage owned: 3.09% (17.6m shares)
Welch (David F) Individual Investor
Percentage owned: 2.2% (12.5m shares)
Alpha Venture Capital Partners, L.P. Corporation
Percentage owned: 2.01% (9.72m shares)
Patel (Samir Rashmikant) Individual Investor
Percentage owned: 1.27% (7.22m shares)
Naydenov (Jordan G) Individual Investor
Percentage owned: 1.08% (6.14m shares)
Similar to CYDY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.